Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance

BRAINSTORM CELL THERAPEUTICS INC.

Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
Company plans to meet $2.5M minimum stockholders' equity requirement as alternative to MVLS compliance.
Extension conditioned on demonstrating compliance with Nasdaq Listing Rule 5550 and progress in capital raising.
Company cannot assure success in raising capital or satisfying equity requirement by the extension date.
Plan presented at February 25, 2025 hearing; capital raising activities are a key component.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.